Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?  by Albersen, Maarten & Bivalacqua, Trinity J.
EBioMedicine 5 (2016) 28–29
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryRegenerative Medicine for Erectile Dysfunction Following Radical
Prostatectomy: Are we Ready?Maarten Albersen a,⁎, Trinity J. Bivalacqua b,c
a Department of Urology, Universtity Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
b The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
c Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins Medical Institutions, Baltimore, MD, USADOI of original article: http://dx.doi.org/10.1016/j.ebi
⁎ Corresponding author.
E-mail addresses:maarten.albersen@uzleuven.be (M.
(T.J. Bivalacqua).
http://dx.doi.org/10.1016/j.ebiom.2016.02.033
2352-3964/© 2016 Published by Elsevier B.V. This is an oa r t i c l e i n f o cellular mixture was thoroughly investigated and it was shown thatAvailable online 19 February 2016
1.5 (±SD: 0.8)% of the cells where ﬁbroblastoid colony forming units,
a subset of which probably represents true mesenchymal stem cells.
The authors state that 26% are stromal cells and the markers that are
used to deﬁne stromal cells in the stromal vascular fraction cells are in-In an elegantly written paper, Haahr and colleagues from Odense,
Denmark, document the ﬁrst phase 1 trial using autologous adipose-
derived regenerative cells in patients with erectile dysfunction follow-
ing radical prostatectomy. These results have long been awaited. In
2010, Tom Lue's group atUCSF published theﬁrst preclinical data on ad-
ipose tissue derived stem cell treatment in a rat model of cavernous
nerve neuropraxia (a model that accurately and efﬁciently represents
the pathophysiology of erectile dysfunction following nerve-sparing
radical prostatectomy) (Albersen et al., 2010). Now six years later, the
ﬁrst clinical trial studying injection of regenerative cells derived from
adipose tissue is published in EBioMedicine (Haahr et al., 2016). The ad-
vent of the ﬁrst clinical data forces us as a scientiﬁc community to con-
template on whether or not we are ready for clinical translation of stem
cell therapy for a non-lethal disease.
1. Safety
The trial described is a phase 1 trial, indicating that the primary goal
of the project was to evaluate the safety of (in this case) intracavernous
injection of autologous unexpanded processed lipo-aspirate, which also
has been named adipose stromal vascular fraction (SVF), or as the au-
thors propose, adipose-derived regenerative cells. These cells where
harvested using the automated processing Celution® 800/CRS system
(Cytori Therapeutics, San Diego, California, USA). Since the harvesting,
processing and injection are typically done in one session, it is of capital
importance that we gain insight into the contents of the resulting prod-
uct. The authors clearly showed that the number of injected cells is a di-
rect derivative of the volume of the lipo-aspirate. Furthermore, they
show that the ageof thepatient has no signiﬁcant inﬂuence on the num-
ber of cells per gram of adipose tissue in the ﬁnal processed product.
Whether the regenerative capacity of the cellular lysate is impaired
with increasing age remains to be elucidated. The composition of theom.2016.01.024.
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et al. on behalf of the International Federation for Adipose Therapeutics
and Science (IFATS) and the International Society for Cellular Therapy
(ISCT) (Bourin et al., 2013). However the true stem cell population
within can only be identiﬁed by additional criteria including plastic ad-
herence, the ability to differentiate into adipocytes, osteocytes and
chondrocytes and a subset of surface markers that is different from
those used in the current study. However, the beneﬁts of direct process-
ing possibly outweigh the risks of contamination and possible dediffer-
entiation of autologous cell cultures. The most important fact is that an
overview was given on the contents of the ﬁnal injected product. The
number of cells ranged between 8.4 and 37.2 million cells and is there-
fore quite variable frompatient to patient. The variability in cell number
administered would no doubt have direct effects on the clinical out-
come. The optimal concentration must be determined in later efﬁcacy
studies, and preliminary analyses of the correlation between concentra-
tion of cellular lysate, safety, as well as erection recovery were not pre-
sented by the authors.
Of capital importance is the fact that no serious adverse events were
reported. Adverse events were recorded at each visit by inspection of
the injection site and posing the patients an open question, “Did you ex-
perience any discomfort related to the operation since the last visit?”,
followed by speciﬁc questions regarding pain, bleeding and swelling at
the liposuction site as well as at the penis area. Five patients reported
minor events which can be classiﬁed as Clavien Dindo grade I and were
mostly related to the liposuctionprocedure rather than the injection itself.
Local penile complaints were limited to one patient reporting penile and
scrotal hematoma. Nomarkers of systemic responsewere assessed in this
study thus we cannot determine if systemic changes occurred.2. Efﬁcacy
In the study by Haahr and colleagues, in the incontinent group, 5/6
patients underwent non-nerve sparing prostatectomywhile in the con-
tinent group, 7/11 patients had some degree of nerve-sparing surgery.
Thus, 8/17 patients in total had some degree of nerve sparing surgery,C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cacy data, 9/17 patients were not able to have successful intercourse,
and 8/17 patients were able to have successful sexual intercourse. Is
this a coincidence? Are the patientswith somedegree of erection recov-
ery the 8 patients who underwent some degree of nerve sparing sur-
gery? Without additional information about the study cohort we
cannot determine if the erection recovery was an effect of regenerative
cell injection versus a spontaneous recovery which is to be expected
after nerve-sparing surgery (Kaye et al., 2013). One could argue against
this positionby stating that 4 patientswhohad an improvement in erec-
tile function where excluded. Early signs of erection recovery however,
in our opinion, do not exclude the possibility for later spontaneous im-
provement of erectile function. The mean time from surgery in the cur-
rent study was 10.1 months, and it is established that erectile function
recovery after nerve sparing radical prostatectomy occurs up to
24 months after surgery (Rabbani et al., 2010).
In the absence of a control group, we simply cannot make any con-
clusion on the efﬁcacy of the proposed regenerative therapy. A power
analysis for efﬁcacy data is lacking, and the incontinent group should
not be considered an “internal control” for the following reasons —
(1) the rate of nerve sparing surgery in the incontinent group was
much lower, (2) authors have described that in their own experience,
these patients historically have an impaired erectile recovery and
(3) it is well established from centers of excellence that non-nerve spar-
ing results in delayed recovery of continence (Kaye et al., 2013;
Gandaglia et al., 2012). As the authors suggested, the efﬁcacy of autolo-
gous adipose-derived regenerative cells in patients with erectile dys-
function following radical prostatectomy needs to be studied in an
adequately powered, randomized and placebo-controlled trial, before
any recommendation can bemade on the (future) use of this treatment.
Even though the wording “potential efﬁcacy” has been used, we believe
for the above mentioned reasons that a phase 1 trial is not designed for
efﬁcacy evaluation.We have to be rigorous and critical with our conclu-
sions so that others in academic and private centers throughout the
world do not prematurely start utilizing this form of local cell-based
therapywithout appropriately powered studieswhich show true efﬁca-
cy. The erectile dysfunction market is large and continues to grow. The
risks ofﬁnancial interests cannot be overestimated and caution is there-
fore warranted in disseminating and interpreting the reported prelimi-
nary efﬁcacy data.
3. Ready for translation? Dosage and timing of treatment
The International Society for Stem Cell Research (ISSCR) devised
guidelines for clinical translation of stem cell-based therapies which in-
clude guidance on the preclinical work up of stem-cell based therapies
and the processes involved in clinical translation. Some of the statements
pertain to preclinical investigation ofmode of action inmodels that close-
ly resemble the disease state. In young rats, known for their surprising
potential for regeneration after injury, we observed only a partial (but
signiﬁcant) recovery of erectile function following cavernous nerve injury
(Albersen et al., 2010) after penile injections of high dosages (1 ∗ 106 cells
in animals weighing under 300 g: ±3 ∗ 106 cells/kg) of pure populations
of cultured adipose tissue derived stem cells. This clinical trial involves
dosages of 8.4 and 37.2 million cells in men with a mean age of
63 years and a mean BMI of 30.3 kg/m2. Assuming, based on their BMI,
that these patientsweighed at least 80 kg, they received roughly between
1 ∗ 105 and 5 ∗ 105 cells/kg body weight. How does this compare to the
situation in a small rodent model? Before we can translate this form of
cell-based therapy, concentration response studies, as preliminary re-
ported by Yiou et al. (2015) for bone marrow mononuclear cells, must
be conducted. We need to know what minimal concentration of cells
could be effective, and what maximal concentration of cells could be
safe. The further these two numbers are apart, the better for translational
efﬁcacy. In our research we have observed that a critical time-point in
cavernous nerve neuropraxia is the ﬁrst 24 to 48 h after nerve injury,when neuro-inﬂammation is initiated and inﬂux of neurotoxic subpopu-
lations of macrophages commences (unpublished data and Albersen
et al., 2013a). Injected adipose derived stem cells are attracted to the in-
jured neural tissue by the local release of chemokines and cytokines,
which is also activated shortly after the initiating events. Several days
later, stem cells appear to reside in reticulo-endothelial system sites
such as the spleen and bone marrow (Lin et al., 2011). Due to the highly
vascular character of the corpus cavernosum, cells disappear rapidly from
the penis and deﬁnitive evidence of engraftment and differentiation into
cell types contained with the corpora has never been established
(Albersen et al., 2013b). Although secondary prevention or treatment ex-
cludes patients who might recover spontaneously from unnecessary
treatment,we hypothesize that early injection, at the timeof radical pros-
tatectomy as a primary prevention of erectile dysfunctionmay be amore
valid physiologic-based approach, and potentially more effective, which
further spares the patients a separately-timed invasive procedure.
4. Future perspectives
We do realize that our comments on the efﬁcacy data in the manu-
script by Haahr and colleagues have a negative connotation. This
stems from our opinion, and we are convinced the authors share this
viewpoint, that any novel therapy offered to our patients should at
least undergo rigorously conducted phase 1 and 2 trials before we can
consider a novel therapy safe and effective. However, the caution and
criticism are intended in a positive and constructive fashion and we ap-
plaud the work that the authors have conducted with the intent of pro-
viding their patients with a difﬁcult-to-treat sexual dysfunction hope
for recovery. There is no doubt that the work conducted by Haahr and
colleagues is novel, and extremely important for the advancement of
the ﬁeld of regenerative medicine, and we are eager to witness further
progress in the clinical development of their ﬁndings.
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